OXNAD1

Across TCGA pan-cancer cohorts, OXNAD1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of OXNAD1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where OXNAD1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types OXNAD1 is over-expressed in tumor, although a few such as CCRCC and PDAC show the opposite, repressed pattern.

CCRCC, PDAC, and COAD are the cancer types where OXNAD1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in OXNAD1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	All	−1.247	<.001	12	view →
PDAC	Female	All	−0.732	<.001	6	view →
COAD	Male	III,IV	+0.419	.002	5	view →
OV	All	All	−0.393	.047	2	view →
LSCC	Male	All	+0.178	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

OXNAD1–CCRCC

Open the CCRCC breakdown →